Common drug repurposed in bold bid to slow devastating nerve disease
NCT ID NCT06249867
Summary
This study is testing whether darifenacin, a medication usually used for overactive bladder, can help slow the progression of ALS (Lou Gehrig's disease). Researchers believe it might protect the connections between nerves and muscles. The trial will involve 30 people with ALS who will take either the drug or a placebo daily for 24 weeks to check its safety and see if it helps maintain function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montreal Neurological Institute
RECRUITINGMontreal, Quebec, H3A 2B4, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Ottawa Hospital Research Institute
RECRUITINGOttawa, Ontario, K1Y 4E9, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.